DilawarKhanMD

Oncology • Rome, GA

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Khan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Khan's full profile

Already have an account?

Office
255 W 5th St Sw
Rome, GA 30165
Phone+1 706-295-3855

Fax+1 706-235-5875
Is this information wrong?

Education & Training

University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Tennessee Medical Center at KnoxvilleResidency, Internal Medicine, 1993 - 1996
NYU Grossman School of MedicineInternship, Transitional Year, 1992 - 1993
Allama Iqbal Medical CollegeClass of 1990

Certifications & Licensure

GA State Medical License 2003 - 2025
NY State Medical License 2012 - 2017
KY State Medical License 2000 - 2004
VA State Medical License 1996 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2013

Clinical Trials

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia
Mariam Fatima, Salik Javed Kakar, Fazal Adnan, Khalid Khan, Afsar Ali Mian, Dilawar Khan> ;BMC Cancer. 2021 Jun 17
29 citations
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Fo...> ;International Journal of Hematology. 2017 Sep 1

Press Mentions

Senate Body for Provision of CT Scan, MRI Machines to PolyclinicSeptember 20th, 2021
Senate Body to Call Former Polio Focal Person to Explain Rise in CasesMarch 12th, 2020
Balvinder, Ravinder Excel in Baisakhi MarathonApril 9th, 2019
Join now to see all

Hospital Affiliations

Piedmont CartersvilleCartersville, Georgia
Atrium Health Floyd Medical CenterRome, Georgia
AdventHealth RedmondRome, Georgia